Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARIA-2: Bioavailability of AQ280 Formulations in Healthy Participants
NCT07093008Phase 1Completed
- Sponsor
- Aqilion
- Start
- Jun 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AQ280 in eosinophilic esophagitis (EoE) (4 arms), sponsored by Aqilion. Primary endpoints: Ratio of Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity for AQ280 Capsule vs Oral Suspension, Ratio of Maximum Observed Concentration for AQ280 Capsule vs Oral Suspension and 7 more. Started Jun 2025; status: completed.
02
Drugs
AQ280
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT07093008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07093008.